What is the main difference between Rituxan and Ocrevus for people with PPMS?
Both drugs target the CD20 molecule on B cells and lead to B cell depletions. Rituxmab has a mouse based protein backbone and Ocrelizumab has a humanized backbone. Ocrelizumab is the only one of the two which has received FDA approval for PPMS.
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research and Ambulatory Care
Department of Neurology and Neurotherapeutics
Director, Transverse Myelitis, Neuromyelitis Optica Programs
Co-Director, Pediatric CONQUER Program
UT Southwestern Medical Center